Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TenCRAOS
2024-517606-29-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in central retinal artery occlusion (CRAO) comparing Tenecteplase + placebo with Acetylsalicylic acid + placebo (2 arms). Primary endpoint: Best-corrected visual acuity improvement at 30 days (ITT). Planned start Oct 2024; status: authorised.
02
Drugs
tenecteplase
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on 2024-517606-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517606-29-00.